Treatment of sepsis in cardiac surgery: Role of immunoglobulins

Perfusion

Volumn 16, Issue 2, 2001, Pages 113-120

  Sablotzki, A ^a   Muhling J ^b   Dehne, M G ^b   Zickman, B ^b   Silber, R E ^a   Friedrich, I ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; CENTOXIN; CORTICOSTEROID; CYTOKINE; EDOBACOMAB; ENDOTOXIN ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; PLACEBO; PROSTAGLANDIN E; UREIDOPENICILLIN DERIVATIVE;

ARTICLE; CARDIOPULMONARY BYPASS; CELL INTERACTION; CHEMOPROPHYLAXIS; CYTOKINE RELEASE; ENDOTHELIUM; ENDOTOXEMIA; HEART SURGERY; HUMAN; IMMUNE RESPONSE; INCIDENCE; INFECTION; INFECTION SENSITIVITY; INFLAMMATION; INJURY; MEDIATOR; MULTIPLE ORGAN FAILURE; NEUTROPHIL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

CARDIOPULMONARY BYPASS; CYTOKINES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFLAMMATION MEDIATORS; SEPSIS;

EID: 0035048611     PISSN: 02676591     EISSN: None     Source Type: Journal    
DOI: 10.1177/026765910101600205     Document Type: Article

References (84)

1. Role of cytokines in the pathogenesis of cardiopulmonary-induced multisystem organ failure
2. SIRS - The systemic inflammatory response syndrome after cardiac operations
3. The systemic inflammatory response to cardiopulmonary bypass: Pathophysiological, therapeutic, and pharmacological considerations
4. Systemic inflammatory response syndrome after cardiac operations
5. IL-6 and TNF-alpha release in association with neutrophil activation after cardiopulmonary bypass surgery
6. Induction of interleukin-8 expression during cardiopulmonary bypass
7. Alterations of the cytokine network in patients undergoing cardiopulmonary bypass
8. Cytokine and lipid mediator blood concentrations after coronary artery surgery
9. Endotoxin release and tumor necrosis factor formation during cardiopulmonary bypass
10. Induction of interleukin-6 synthesis on the myocardium
11. Cytokine and complement levels in patients undergoing cardiopulmonary bypass
12. Monocyte expression of interleukin-8 in response to oxidant stress
13. Prognostic values of serum cytokines in septic shock
14. Circulating cytokines in patients undergoing normothermic cardiopulmonary bypass
15. Interleukin-6: An overview
16. Does the duration of cardiopulmonary bypass or aortic cross-clamp, in the absence of blood and/or blood product administration, influence the IL-6 response to cardiac surgery?
17. Plasma cytokine and endotoxin levels correlate with survival in patients with sepsis syndrome
18. Arterial and venous cytokine response to cardiopulmonary bypass for low risk CABG and relation to hemodynamics
19. Impact of left ventricular dysfunction on cytokines hemodynamics, and outcome in bypass grafting
20. Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization
21. A potential mechanism of vasodilation after warm heart surgery. The temperature-dependent release of cytokines
22. Inflammatory reaction and capillary leak syndrome related to cardiopulmonary bypass in neonates undergoing cardiac operations
23. Cytokine mediators of immunity and inflammation
24. Changes in white blood cells, immunosuppressive acidic protein and interleukin-2 receptor after open heart surgery
25. Alterations of cell-mediated immune response following cardiac surgery
26. Major injury leads to predominance of the T helper-2 lymphocyte phenotype and diminished interleukin-12 production associated with decreased resistance to infection
27. Plasma levels of immunoinhibitory cytokines interleukin-10 and transforming growth factor-β in patients undergoing coronary artery bypass grafting
28. Interleukin 10
29. IL-10 inhibits cytokine production by activated macrophages
30. Deactivation of macrophages by transforming growth factor-β
31. Inflammatory and immuno-modulatory roles of TGF-β
32. IL-10 synergizes with IL-4 and transforming growth factor-β to inhibit macrophage cytotoxic activity
33. Circulating adhesion molecules in pediatric cardiac surgery
34. Plasma levels of selectins and interleukins in cardiovascular surgery using cardiopulmonary bypass
35. Inhibition of neutrophil adherence improves postischemic ventricular performance of the neonatal heart
36. Complete prevention of myocardial stunning, contracture, low-reflow, and edema after heart transplantation by blocking neutrophil adhesion molecules during reperfusion
37. Neutrophil-mediated pulmonary injury in a canine model of cardiopulmonary bypass: Evidence for a CD18-dependent mechanism
38. Neutrophil-induced oxidative injury of cardiac myocytes: A compartmented system requiring CD11b/CD18-ICAM-1 adherence
39. Deposition of terminal C5b-9 complement complexes on erythrocytes and leukocytes during cardiopulmonary bypass
40. Complement activation by whole endotoxin is blocked by a monoclonal antibody to factor B
41. Immunomodulation by bacterial endotoxin
42. The effect of methylprednisolone on endotoxemia and complement activation during cardiac surgery
43. Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans
44. Steroid inhibition of cytokine-mediated vasodilation after warm heart surgery
45. Glucocorticoids reduce bronchial epithelial inflammation during cardiopulmonary bypass
46. Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome: Results from a randomized, double-blind, placebo-controlled trial
47. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis
48. HA-1A Sepsis Study Group. Treatment of gram negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: A randomized, double-blind, placebo-controlled trial
49. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol)
50. The proteinases in shock
51. Platelet-activating factor antagonists (BN52021 and BN50730) inhibit tumor necrosis factor-alpha-mediated cytotoxicity on murine L929 tumor cells
52. Does aprotinin inhibit cardiopulmonary bypass-induced inflammation?
53. A prospective randomized study of a modified technique of ultrafiltration during pediatric open-heart surgery
54. Ultrafiltration and modified ultrafiltration in pediatric open heart operations
55. Hemofiltration during cardiopulmonary bypass in pediatric cardiac surgery
56. Cytokine production and hemofiltration in children undergoing cardiopulmonary bypass
57. High volume hemofiltration improves hemodynamics and survival in pigs exposed to gut ischemia and reperfusion
58. Infusion of ultrafiltrate from endotoxemic pigs depresses myocardial performance in normal pigs
59. Supplemental immune globulins in sepsis
60. Bacterial lipopolysaccharide (LPS)-specific antibodies in commercial human immunoglobulin preparations: Superior antibody content of an IgM-enriched product
61. Immunoglobulins to group A streptococcal surface molecules decrease adherence to and invasion of human pharyngeal cells
62. In vitro inhibitory activity of tumor necrosis factor alpha and interleukin-2 of human immunoglobulin preparations
63. Effect of whole and fractionated intravenous immunoglobulin on complement in vitro
64. Synergy between acylureidopenicillins and immunoglobulin G in experimental animals
65. Polyvalent immunoglobulins for prophylaxis of bacterial infections in patients following multiple trauma - A randomized, placebo-controlled study
66. Cooperative group of additional immunoglobulin therapy in severe bacterial infections: Results of a multicenter randomized controlled trial in cases of diffuse fibrinopurulent peritonitis
67. Prophylaxe mit einem Pseudomonas-Immunglobulin bei Brandverletzten
68. Adjuvente Therapie mit Pseudomonas-Immunglobulin bei beatmeten Patienten einer operativen Intensivstation
69. Supplemental immunoglobulin therapy in sepsis and septic shock - Comparison of mortality under treatment with polyvalent i.v. immunoglobulin versus placebo: Protocol of a multicenter, randomized, prospective, double-blind trial
70. Polyvalent immune globulins
71. Sepsis and polyspecific intravenous immunoglobulins
72. High-dose intravenous IgG for treatment of severe surgical infections
73. Treatment of gram-negative septic shock with an immunoglobulin preparation. A prospective, randomized clinical trial
74. Anti-endotoxin therapy for fulminant meningococcal septicaemia: Pilot study
75. Comparison of two types of intravenous immunoglobulins in the treatment of neonatal sepsis
76. Early sepsis treatment with immunoglobulins after cardiac surgery in score-identified high-risk patients
77. Evaluation of definitions and parameters for sepsis assessment in patients after cardiac surgery
78. Endotoxin concentrations and therapy with polyclonal IgM-enriched immunoglobulins in neutropenic cancer patients with sepsis syndrome: Pilot study and interim analysis of a randomized trial
79. Impaired B lymphocyte function during open heart surgery: Effects of anaesthesia and surgery
80. Cytokine induction in human mononuclear cells stimulated by IgG-coated culture surfaces and by IgG for infusion
81. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo
82. Immunomodulatory effects of intravenous immunoglobulin G
83. Binding of cytokines to pharmaceutically prepared human immunoglobulin
84. Therapeutic immunomodulatory approaches for the control of systemic inflammatory response syndrome and the prevention of sepsis